LCZ696 (Sacubitril/Valsartan) Can We Predict Who Will Benefit?

Journal of the American College of Cardiology

Volumn 66, Issue 19, 2015, Pages 2072-2074

  Dec, G William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

neprilysn inhibition; sacubitril valsartan

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ENALAPRIL; TETRAZOLE DERIVATIVE;

AGE; ANGIONEUROTIC EDEMA; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; KIDNEY DYSFUNCTION; MORTALITY; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; FEMALE; MALE; PROCEDURES;

AMINOBUTYRATES; ENALAPRIL; FEMALE; HEART FAILURE; HUMANS; MALE; RISK ASSESSMENT; TETRAZOLES;

EID: 84960878963     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.08.877     Document Type: Editorial

References (11)

1. M. Jessup Neprilysin inhibition - a novel therapy for heart failure N Engl J Med 371 2014 1062 1064
2. E. Braunwald The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure J Am Coll Cardiol 65 2015 1029 1041
3. S.D. Solomon, M. Zile, B. Pieske, and et al. The angiotensin-receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
4. J.J. McMurray, M. Packer, A.S. Desai, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993-110
5. M. Packer, J.J. McMurray, A.S. Desai, and et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
6. J. Simpson, P.S. Jhund, J.S. Cardoso, and et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF J Am Coll Cardiol 66 2015 2059 2071
7. S.J. Pocock, C.A. Ariti, J.J. McMurrary, and et al. Predicting survival in heart failure: risk score based on 39,377 patients from 30 studies Eur Heart J 34 2013 1404 1413
8. T.J. Collier, S.J. Pocock, J.J. McMurray, and et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insights from a novel risk score for prognosis derived from the EMPHASIS-HF trial Eur Heart J 34 2013 2823 2829
9. A. Bayes-Genis, J. Barallat, E. Pascual-Figal, and et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure J Am Coll Cardiol HF 3 2015 641 644
10. N. Vodovar, M.R. Seronde, S. Laribi, and et al. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure J Am Coll Cardiol HF 3 2015 629 636
11. A. Bayes-Genis Neprilysin in heart failure. From oblivion to center stage J Am Coll Cardiol HF 3 2015 637 640